Basel, January 29, 2014 - Commenting on the results, Joseph Jimenez, CEO of Novartis, said:"Novartis delivered strong performance in 2013, growing both net sales and core operating income in constant currencies while absorbing patent expirations. We maintained good momentum in innovation, with 18 approvals and 3 FDA Breakthrough Therapy designations. Our growth products continued to expand, rejuvenating our portfolio and reinforcing our growth prospects."
Basel, January 27, 2014 - Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100.
Basel, 24 January, 2014 - Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xolair® (omalizumab) as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. The recommended dose is 300 mg by subcutaneous injection every four weeks.
Basel, January 24, 2014 - Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure by the Committee for Medicinal Products for Human Use (CHMP) following a negative opinion issued today. In accordance with CHMP process a revised opinion could be granted in Q2 2014.
Basel, January 12, 2014 - Novartis announced today, that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect having decided to pursue a career opportunity outside of the organization.
Holzkirchen, Germany, December 19, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie's HUMIRA®) - the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease.
Munich, December 18, 2013 - Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).
Basel, December 9, 2013 - Novartis today announced that patients with myelofibrosis initially randomized to treatment with Jakavi® (ruxolitinib) lived longer than those randomized to treatment with placebo or conventional therapy, as described in several analyses from the Phase III COMFORT-I and COMFORT-II studies.
Basel, December 9, 2013 -Princeton University has announced that a vaccination program with Novartis meningococcal serogroup B (MenB) vaccine, Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), began today following a campus outbreak that has affected at least eight students.